HLA-C and colorectal carcinoma: There remains a need for population-tailored neoantigen panels with broad HLA coverage and functional validation.<h4>Methods</h4>We developed a colorectal cancer (CRC)-specific OTS neoantigen panel by integrating TCGA mutation data with HLA class I binding predictions across 68 alleles (18 HLA-A, 34 HLA-B, and 16 HLA-C), covering both Asian and Caucasian populations.